Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21837387 | 0.92 | ITGB3 (0.47) | ABCB1ITGB3ITGA2BALDH1A1CTSL | |
| SCHEMBL21837512 | 0.92 | ITGB3 (0.47) | ABCB1ITGB3ITGA2BALDH1A1CTSL | |
| SCHEMBL14842127 | 0.91 | ABCB1 (0.52) | ABCB1ITGB3ITGA2BALDH1A1CTSL | |
| SCHEMBL25185926 | 0.86 | CTSK (0.47) | ABCB1ITGB3ITGA2BALDH1A1CTSL | |
| SCHEMBL22092025 | 0.86 | ITGB3 (0.49) | ABCB1ITGB3ITGA2BALDH1A1CTSL | |
| SCHEMBL5194032 | 0.86 | ITGB3 (0.52) | ABCB1ITGB3ITGA2BALDH1A1CTSL | |
| SCHEMBL25178768 | 0.86 | ABCB1 (0.50) | ABCB1ITGB3ITGA2BALDH1A1CTSL | |
| SCHEMBL5192318 | 0.86 | ABCB1 (0.47) | ABCB1ITGB3ITGA2BALDH1A1CTSL | |
| SCHEMBL17669880 | 0.85 | ABCB1 (0.49) | ABCB1ITGB3ITGA2BALDH1A1CTSL | |
| SCHEMBL22091943 | 0.83 | ITGB3 (0.43) | ABCB1ITGB3ITGA2BALDH1A1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839641-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-12-12 | — | — | US | disclosed |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2017-05-11 | — | — | US | disclosed |
| US-9540394-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160130281-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC. | 2016-05-12 | — | — | US | disclosed |
| US-9187495-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20150203513-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2015-07-23 | — | — | US | disclosed |
| US-8889671-B2 | Compounds and methods for treating bacterial infections | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206677-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | ABCB1 251/4885ITGB3 1875/4885ITGA2B 2107/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | ABCB1 1072/4885ITGB3 1622/4885ITGA2B 2752/4885 |
| US-20160130281-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | ABCB1 251/4885ITGB3 1875/4885ITGA2B 2107/4885 |
| US-20150203513-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | ABCB1 251/4885ITGB3 1875/4885ITGA2B 2107/4885 |
| US-20170128458-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NISCH, ELANE, ALPI | ABCB1 251/4885ITGB3 1875/4885ITGA2B 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.